However, caveats considered, the authors write, If true, our data anticipate increasing numbers of NAION cases related to this class of drugs. They believe that their research is the first to find a link between NAION risk and semaglutide
incorrect dosing may exacerbate these effects Gallbladder problems GLP-1 receptor agonist use has been associated with gallbladder disease, including gallstones and cholecystitis Hypoglycaemia If retatrutide is used alongside insulin or sulfonylureas, there is an increased risk of low blood glucose Call 999 or go to A&E immediately if you experience: Difficulty breathing, throat swelling, or any signs of anaphylaxis Severe abdominal pain (which may indicate pancreatitis or a gallbladder problem) Rapid heart rate, dizziness, or collapse following injection Contact your GP or NHS 111 if you experience: Persistent nausea, vomiting, or inability to tolerate food or fluids Signs of infection at the injection site (increasing redness, warmth, swelling, or discharge) Upper right abdominal pain or pain radiating to the shoulder (possible gallbladder symptoms) Any unexpected or concerning symptoms following use If you feel unwell after using an unlicensed injectable, stop use immediately and bring the vial and any packaging with you when seeking medical attention, as this will assist healthcare professionals in assessing your situation
Semaglutide: If a dose of Semaglutide is missed, it should be taken as soon as possible within 5 days after the missed dose
Regarding CYP2E1 mRNA level, it increased in the APAP group when compared to the control group ( p 0.001)
